Home / Drug development / Preclinical / Preclinical drug substance manufacturing
Preclinical drug substance manufacturing
Our preclinical drug substance development teams specialize in solving complex chemistry that may fail elsewhere. We convert medicinal chemistry routes into practical, reproducible large-scale processes for IND-enabling studies and deliver non-GMP material to support toxicology and preclinical research.
From the start, we identify scale-up risks and resolve them through deep scientific insight, where we apply flow chemistry, biocatalysis, chemo-catalysis, and chiral synthesis to make challenging transformations work at scale.
Close collaboration between discovery and process chemists ensures knowledge is shared in real time, reducing rework, maintaining momentum, and keeping your candidate on track toward IND.
From discovery chemistry to IND-ready supply
Expert-led CMC development
Our senior chemists bring experience in route design, process optimisation, and CMC scale-up, helping to translate complex discovery chemistry into reliable, manufacturable drug substance supply for IND.
Direct connection between discovery and development
Discovery and scale-up teams collaborate from the start, sharing data and process insight to reduce rework, maintain momentum and keep preclinical timelines on track.
Specialist technologies that unlock scale
Advanced flow chemistry, biocatalysis, chemo-catalysis, and chiral chemistry solve challenging transformations and deliver robust, phase-appropriate processes for IND-enabling studies.
Thinking ahead in preclinical drug development
We connect CMC drug substance development with ADME-Tox, solid-state chemistry, formulation and analytical development to keep preclinical programs moving toward IND.
Our teams develop scalable, GMP-ready processes and fully characterise each molecule and each batch thoroughly to ensure data, materials, and documentation are ready for regulatory submission – without delays.
What do our partners say?
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
Your discovery and development partner
Symeres supports small-molecule programs from discovery through early and late development. Our teams in Europe and North America provide chemistry, biology, ADME-Tox, and CMC drug substance and drug product development expertise. We share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous. Projects can run as standalone studies or as coordinated, multi-disciplinary programs.
Resources we think you'll love
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Whitepaper
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Whitepaper
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our preclinical IND/IMPD scale-up experts
See how we can support the discovery and development of your next breakthrough.